Moderna reports 44% downturn in 3rd-qtr 2023 sales
US mRNA specialist Moderna (Nasdaq: MRNA) today reported financial results for the third quarter of 2023 that disappointed, sending its shares down 8.9% to $69.23 in early trading.
Moderna reported $1.8 billion in Spikevax (COVID-19 vaccine) sales in the third quarter of 2023, down 44% on the like 2022 quarter. This compares to $1.40 billion expected by analysts. The sales figure comprises $0.9 billion of US sales and $0.8 billion of international sales.
This leads to $3.9 billion in vaccine sales for the year through the third quarter. The company believes that the US market for fall 2023 will be at least 50 million doses, supporting total 2023 Spikevax sales of at least $6 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze